Q1 EPS Estimates for Sanara MedTech Reduced by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Equities researchers at HC Wainwright dropped their Q1 2025 earnings estimates for Sanara MedTech in a research report issued to clients and investors on Wednesday, March 26th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.31) per share for the quarter, down from their previous estimate of ($0.26). HC Wainwright has a "Buy" rating and a $51.00 price objective on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech's Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($1.12) EPS.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. The firm had revenue of $26.31 million for the quarter, compared to the consensus estimate of $22.75 million.

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $46.00 price target on shares of Sanara MedTech in a research note on Wednesday, March 26th.

Sanara MedTech Price Performance

NASDAQ:SMTI traded down $0.55 during mid-day trading on Friday, reaching $30.32. 7,066 shares of the company were exchanged, compared to its average volume of 23,161. The company has a fifty day moving average of $34.22 and a 200 day moving average of $33.72. The stock has a market cap of $269.92 million, a PE ratio of -30.69 and a beta of 1.37. Sanara MedTech has a 12 month low of $26.00 and a 12 month high of $39.08. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76.

Hedge Funds Weigh In On Sanara MedTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in SMTI. Marshall Wace LLP bought a new position in shares of Sanara MedTech in the 4th quarter worth about $1,005,000. Fifth Third Bancorp bought a new stake in Sanara MedTech in the fourth quarter worth approximately $898,000. Renaissance Technologies LLC lifted its stake in Sanara MedTech by 152.9% in the fourth quarter. Renaissance Technologies LLC now owns 35,400 shares of the company's stock valued at $1,175,000 after buying an additional 21,400 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Sanara MedTech by 234.5% during the 4th quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company's stock worth $451,000 after buying an additional 9,516 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Sanara MedTech by 116.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 15,925 shares of the company's stock worth $529,000 after buying an additional 8,567 shares during the period. Institutional investors own 8.10% of the company's stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.